Lysosomal storage disorders result from a wide spectrum of genetic mutations affecting proteins integral to normal lysosomal function. Defects in no less than 50 proteins have been documented to cause lysosomal dysfunction, and new proteins linked to lysosomal disease continue to be discovered. Lysosomal diseases are known to affect many tissues and organs with most significantly impacting the brain, leading to severe cognitive impairment including dementia, ataxia, tremors and related motor system dysfunctions, blindness, deafness and other sensory impairments, psychotic episodes and seizures. This complex array of clinical features is reflected in a diversity of underlying molecular and cellular abnormalities, including ectopic dendritogenesis, neuroaxonal dystrophy, protein aggregation conditions including tauopathy, neurodegeneration, and so forth. We believe that this diversity of impact characteristic of storage diseases affecting brain is best explained by looking beyond the lysosome to broader abnormalities in endosomal, retrosomal, autophagosomal, and proteasomal systems, what we refer to as the 'Greater Lysosomal System'. Importantly, there is also increasing evidence that lysosomal diseases are not simply states of storage but are also states of deficiency, with failure to salvage degraded substrates from diseased lysosomes leading to shortages of critical precursors for other metabolic processes. Taken together, this new concept of lysosomal disease stresses the importance of viewing the lysosome and its processing streams not simply as a passive digestive process but rather as an integral player in far reaching cellular events, from signal transduction to homeostatic regulation. In order to advance understanding of lysosomal diseases affecting brain and to illuminate the role of the greater lysosomal system as a metabolic regulator in normal neurons, we propose a series of research aims to test hypotheses that attempt to explain the development of two of the most well documented but enigmatic features of many lysosomal diseases - ectopic dendritogenesis and neuroaxonal dystrophy. Delineation of these pathogenic pathways and the underlying role of the lysosomal system we believe will open the door to understanding, and treating, commoner neurodegenerative diseases that share similar features, from Fragile X and other dendritopathies to dementias like Alzheimer's disease.
While individually rare, lysosomal diseases as a whole have an incidence of 1 in 7,000 live births, and are therefore as a group one of the more common types of genetic disease. At least two thirds of these diseases affect brain and typically cause years to decades of intellectual and motor/sensory system decline, with severe consequences for both patients and families. Few treatments are available for lysosomal disorders affecting brain, and almost all are invariably fatal. To better develop therapies we need to know more about pathogenesis - how defects in what has been considered an inert, end-organelle ultimately causes such serious neurological demise. This proposal provides a new way of thinking about lysosomes and lysosomal diseases and presents a series of testable hypotheses that we believe will provide new insights into the role of the lysosomal system in neurons in both health and disease, including in common neurodegenerative disorders for which lysosomal compromise has been implicated (e.g., Alzheimer's and Parkinson's diseases).
|Micsenyi, Matthew C; Sikora, Jakub; Stephney, Gloria et al. (2013) Lysosomal membrane permeability stimulates protein aggregate formation in neurons of a lysosomal disease. J Neurosci 33:10815-27|
|Stromme, Petter; Dobrenis, Kostantin; Sillitoe, Roy V et al. (2011) X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of endosomal-lysosomal dysfunction. Brain 134:3369-83|
|Zhou, Sharon; Davidson, Cristin; McGlynn, Robert et al. (2011) Endosomal/lysosomal processing of gangliosides affects neuronal cholesterol sequestration in Niemann-Pick disease type C. Am J Pathol 179:890-902|
|Damme, Markus; Stroobants, Stijn; Walkley, Steven U et al. (2011) Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in ?-mannosidosis. J Neuropathol Exp Neurol 70:83-94|
|Ulatowski, L; Parker, R; Davidson, C et al. (2011) Altered vitamin E status in Niemann-Pick type C disease. J Lipid Res 52:1400-10|
|Curcio-Morelli, Cyntia; Charles, Florie A; Micsenyi, Matthew C et al. (2010) Macroautophagy is defective in mucolipin-1-deficient mouse neurons. Neurobiol Dis 40:370-7|
|Walkley, Steven U; Sikora, Jakub; Micsenyi, Matthew et al. (2010) Lysosomal compromise and brain dysfunction: examining the role of neuroaxonal dystrophy. Biochem Soc Trans 38:1436-41|
|Walkley, S U (2009) Pathogenic cascades in lysosomal disease-Why so complex? J Inherit Metab Dis 32:181-9|
|Davidson, Cristin D; Ali, Nafeeza F; Micsenyi, Matthew C et al. (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4:e6951|
|Walkley, Steven U; Vanier, Marie T (2009) Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta 1793:726-36|
Showing the most recent 10 out of 17 publications